Letters to the Editor

Clarification for Apixaban Dosing in Patients with Impaired Renal Function

 

Am Fam Physician. 2018 Apr 15;97(8):496-497.

Original Article: Deep Venous Thrombosis and Pulmonary Embolism: Current Therapy

Issue Date: March 1, 2017

See additional reader comments at: https://www.aafp.org/afp/2017/0301/p295.html

To the Editor: We thank the authors for a very well-written and thorough review of the current treatment landscape for deep venous thrombosis and pulmonary embolism. Table 1 reviews direct oral anticoagulant dosing, including renal dose adjustments. Apixaban (Eliquis) renal dosing was included as 2.5 mg orally twice daily if at least one criterion is met: serum creatinine 1.5 mg per dL (133 μmol per L) or more, age 80 years or older, or weight 60 kg (132 lb, 4 oz) or less. The AMPLIFY trial looked at apixaban for treatment of deep venous thrombosis/pulmonary embolism and excluded patients with a serum creatinine level of 2.5 mg per dL (221 μmol per L) or greater, or a creatinine clearance less than 25 mL per minute per 1.73 m2 (0.42 mL per second per m2).1 On the other hand, per the manufacturer, no dosage adjustment is required for renal function, although it is noted that patients with a creatinine clearance less than 15 mL per minute per 1.73 m2 (0.25 mL per second per m2) and patients on dialysis were not included in clinical trials; all the conclusions we drew from the literature regarding these patients were based on pharmacokinetic and pharmacodynamic (anti–factor Xa activity) data.2,3 The dosing the authors list in Table 1 is most similar to dosing guidelines for reduction of the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation. However, t hat recommendation requires an adjustment to the 2.5-mg dose when two of the three criteria are met based on the ARISTOTLE and AVERROES trials.4,5 Given this contradictory information, we would appreciate some clarification on the need to adjust apixaban dosing in patients with impaired renal function.

Author disclosure: No relevant financial affiliations.

References

show all references

1. Agnelli G, Buller HR, Cohen A, et al. Apixaban for extended treatment of venous thromboembolism. N Engl J Med. 2013;368(8):699–708....

2. Eliquis (apixaban) [product monograph]. Pfizer Canada, Inc.; 2018. Accessed March 25, 2018 at: https://www.pfizer.ca/sites/g/files/g10045006/f/201803/ELIQUIS_PM_211430_26Feb2018_marketed_E.pdf.

3. Wang X, Tirucherai G, Marbury TC, et al. Pharmacokinetics, pharmacodynamics, and safety of apixaban in subjects with end-stage renal disease on hemodialysis. J Clin Pharmacol. 2016;56(5):628.636.

4. Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365(11):981–992.

5. Connolly SJ, Eikelboom J, Joyner C, et al. Apixaban in patients with atrial fibrillation. N Engl J Med. 2011;364(9): 806–817.

In Reply: Thank you for your inquiry regarding our article. In Table 1, we recommended modified dosing of apixaban (2.5 mg twice daily) if at least one of the following criteria is met: serum creatinine 1.5 mg per dL (133 μmol per L) or greater, age 80 years or older, weight 60 kg (132 lb, 4 oz) or less. However, as Drs. Naik and Ragheb correctly state, the manufacturer does not recommend any adjustment for renal insufficiency, age, or weight when treating venous thromboembolism.1 According to the U.S. Food and Drug Administration, no renal adjustment is necessary for apixaban when used to treat venous thromboembolism, even in patients with end-stage renal disease and/or patients on hemodialysis.2

To our knowledge, the only clinical trial that addresses the question of apixaban use for venous thromboembolism in patients with impaired renal function is the AMPLIFY study.3 Patients were excluded from the study if the serum creatinine level was greater than 2.5 mg per dL (221 μmol per L) or the calculated creatinine clearance was less than 25 mL per minute per 1.73 m2 (0.42 mL per second per m2). However, no dosage adjustments were made for patients in the study with mild renal dysfunction.

Upon further consideration and to provide a recommendation that is most consistent with current knowledge, we would like to remove our recommendation for dose adjustment of apixaban. However, we recommend careful monitoring for any patient prescribed apixaban for venous thromboembolism whose renal function falls outside of the population that was studied in clinical trials.

Author disclosure: No relevant financial affiliations.

References

1. PDR.net. Eliquis (apixaban)-drug summary. 2016. http://www.pdr.net/drug-summary/Eliquis-apixaban-3039. Accessed December 9, 2017.

2. Food and Drug Administration. Eliquis label. https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/202155s012lbl.pdf. Accessed on December 9, 2017.

3. Agnelli G, Buller HR, Cohen A, et al. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med. 2013;369(9):799–808.

Send letters to afplet@aafp.org, or 11400 Tomahawk Creek Pkwy., Leawood, KS 66211-2680. Include your complete address, e-mail address, and telephone number. Letters should be fewer than 400 words and limited to six references, one table or figure, and three authors.

Letters submitted for publication in AFP must not be submitted to any other publication. Possible conflicts of interest must be disclosed at time of submission. Submission of a letter will be construed as granting the AAFP permission to publish the letter in any of its publications in any form. The editors may edit letters to meet style and space requirements.

This series is coordinated by Kenny Lin, MD, MPH, Associate Deputy Editor for AFP Online.

 

 

Copyright © 2018 by the American Academy of Family Physicians.
This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP. Contact afpserv@aafp.org for copyright questions and/or permission requests.

Want to use this article elsewhere? Get Permissions

Email Alerts

Don't miss a single issue. Sign up for the free AFP email table of contents.

Sign Up Now

Navigate this Article